Table 4.
Percent difference in tetanus and diphtheria antibody concentrations for each increment increase in child concentrations of PFASs, PCB and mercury in crude and adjusted analyses.
| Tetanus a | Diphtheria a | ||
|---|---|---|---|
|
|
|
|
|
| N | % difference (95 % CI) | % difference (95 % CI) | |
|
| |||
| Crude | |||
| PFHxS (ng/mL serum) | 314 | 28 (−5, 73) | 48 (1, 116) |
| PFHpS (ng/mL serum) | 314 | −20 (−60, 60) | −46 (−77, 30) |
| PFOS (ng/mL serum) | 314 | 3 (−0, 6) | 3 (−1, 7) |
| PFOA (ng/mL serum) | 314 | 21 (−5, 54) | 19 (−12, 61) |
| PFNA (ng/mL serum) | 314 | 17 (−5, 44) | 21 (−7, 57) |
| PFDA (ng/mL serum) | 314 | 74 (12, 168) | 124 (30, 286) |
| PFUnDA (ng/mL serum) | 314 | 38 (0, 89) | 40 (−6, 108) |
| ΣPCB (μg/g lipid) | 314 | 36 (3, 78) | 40 (−1, 97) |
| Mercury (μg/L blood) | 309 | 2 (−1, 6) | 2 (−1, 6) |
| Adjusted b | |||
| PFHxS (ng/mL serum) | 314 | 28 (−6, 73) | 48 (1, 115) |
| PFHpS (ng/mL serum) | 314 | −20 (−60, 60) | −44 (−76, 34) |
| PFOS (ng/mL serum) | 314 | 3 (−0, 6) | 3 (−1, 7) |
| PFOA (ng/mL serum) | 314 | 21 (−5, 54) | 21 (−10, 64) |
| PFNA (ng/mL serum) | 314 | 17 (−5, 44) | 22 (−6, 58) |
| PFDA (ng/mL serum) | 314 | 74 (12, 169) | 126 (32, 289) |
| PFUnDA (ng/mL serum) | 314 | 38 (0, 89) | 42 (−5, 110) |
| ΣPCB (μg/g lipid) | 314 | 36 (3, 79) | 39 (−1, 96) |
| Mercury (μg/L blood) | 309 | 2 (−1, 6) | 3 (−1, 7) |
| Adjusted c | |||
| PFHxS (ng/mL serum) | 314 | −28 (−53, 10) | −40 (−64, 1) |
| PFHpS (ng/mL serum) | 314 | −19 (−66, 91) | −38 (−78, 77) |
| PFOS (ng/mL serum) | 314 | −2 (−5, 2) | −3 (−7, 1) |
| PFOA (ng/mL serum) | 314 | −1 (−24, 29) | −10 (−35, 25) |
| PFNA (ng/mL serum) | 314 | −11 (−30, 13) | −19 (−39, 9) |
| PFDA (ng/mL serum) | 314 | −29 (−61, 28) | −39 (−70, 27) |
| PFUnDA (ng/mL serum) | 314 | −15 (−42, 25) | −27 (−54, 16) |
| ΣPCB (μg/g lipid) | 314 | −2 (−32, 40) | −26 (−52, 15) |
| Mercury (μg/L blood) | 309 | −0 (−3, 3) | −1 (−5, 3) |
| With known vaccination record c,d | |||
| PFHxS (ng/mL serum) | 169 | −38 (−74, 48) | −78 (−94, −25) |
| PFHpS (ng/mL serum) | 169 | −22 (−81, 217) | −85 (−98, 8) |
| PFOS (ng/mL serum) | 169 | −3 (−8, 3) | −9 (−16, −2) |
| PFOA (ng/mL serum) | 169 | −8 (−30, 21) | −22 (−48, 16) |
| PFNA (ng/mL serum) | 169 | −8 (−37, 34) | −39 (−64, 4) |
| PFDA (ng/mL serum) | 169 | −29 (−68, 61) | −59 (−87, 31) |
| PFUnDA (ng/mL serum) | 169 | −1 (−45, 81) | −46 (−77, 25) |
| ΣPCB (μg/g lipid) | 169 | −9 (−53, 76) | −53 (−82, 19) |
| Mercury (μg/L blood) | 166 | −0 (−7, 7) | −3 (−12, 7) |
a
Adjusted for time since vaccine booster/estimated time since vaccine booster.
b
Adjusted for duration of being breastfed (<6 months, 6–12 months, >1 year).
c
Adjusted for duration of being breastfed (<6 months, 6–12 months, >1 year) and area of residence (Nuuk, Maniitsoq, Sisimiut, Ilulissat, Aasiaat, Qeqertarsuaq, Tasiilaq).
d
Including children with known tetanus-diphtheria booster date only.